Literature DB >> 27707764

Shigella Vaccine Development: Finding the Path of Least Resistance.

Wilbur H Chen1,2, Karen L Kotloff3,4,2.   

Abstract

Shigella spp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigella vaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908-917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27707764      PMCID： PMC5139600          DOI： 10.1128/CVI.00444-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  50 in total

1.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

2.  Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Authors:  Karen L Kotloff; Marcela F Pasetti; Eileen M Barry; James P Nataro; Steven S Wasserman; Marcelo B Sztein; William D Picking; Myron M Levine
Journal:  J Infect Dis       Date:  2004-10-19       Impact factor: 5.226

3.  Recommendations regarding the development of combined enterotoxigenic Eschericha coli and Shigella vaccines for infants.

Authors:  Richard I Walker; Allison Clifford
Journal:  Vaccine       Date:  2014-12-08       Impact factor: 3.641

4.  Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Authors:  Justen H Passwell; Shai Ashkenazi; Efrat Harlev; Dan Miron; Reut Ramon; Nahid Farzam; Liat Lerner-Geva; Yonit Levi; Chiayung Chu; Joseph Shiloach; John B Robbins; Rachel Schneerson
Journal:  Pediatr Infect Dis J       Date:  2003-08       Impact factor: 2.129

5.  Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile.

Authors:  C Ferreccio; V Prado; A Ojeda; M Cayyazo; P Abrego; L Guers; M M Levine
Journal:  Am J Epidemiol       Date:  1991-09-15       Impact factor: 4.897

6.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.

Authors:  W G Adams; K A Deaver; S L Cochi; B D Plikaytis; E R Zell; C V Broome; J D Wenger
Journal:  JAMA       Date:  1993-01-13       Impact factor: 56.272

7.  Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Authors:  Karen L Kotloff; Jakub K Simon; Marcela F Pasetti; Marcelo B Sztein; Stacey L Wooden; Sofie Livio; James P Nataro; William C Blackwelder; Eileen M Barry; Wendy Picking; Myron M Levine
Journal:  Hum Vaccin       Date:  2007-07-15

8.  South Asia as a Reservoir for the Global Spread of Ciprofloxacin-Resistant Shigella sonnei: A Cross-Sectional Study.

Authors:  Hao Chung The; Maia A Rabaa; Duy Pham Thanh; Niall De Lappe; Martin Cormican; Mary Valcanis; Benjamin P Howden; Sonam Wangchuk; Ladaporn Bodhidatta; Carl J Mason; To Nguyen Thi Nguyen; Duong Vu Thuy; Corinne N Thompson; Nguyen Phu Huong Lan; Phat Voong Vinh; Tuyen Ha Thanh; Paul Turner; Poda Sar; Guy Thwaites; Nicholas R Thomson; Kathryn E Holt; Stephen Baker
Journal:  PLoS Med       Date:  2016-08-02       Impact factor: 11.069

9.  Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.

Authors:  Franklin R Toapanta; Jakub K Simon; Eileen M Barry; Marcela F Pasetti; Myron M Levine; Karen L Kotloff; Marcelo B Sztein
Journal:  Front Immunol       Date:  2014-08-20       Impact factor: 7.561

10.  Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study.

Authors:  Jie Liu; James A Platts-Mills; Jane Juma; Furqan Kabir; Joseph Nkeze; Catherine Okoi; Darwin J Operario; Jashim Uddin; Shahnawaz Ahmed; Pedro L Alonso; Martin Antonio; Stephen M Becker; William C Blackwelder; Robert F Breiman; Abu S G Faruque; Barry Fields; Jean Gratz; Rashidul Haque; Anowar Hossain; M Jahangir Hossain; Sheikh Jarju; Farah Qamar; Najeeha Talat Iqbal; Brenda Kwambana; Inacio Mandomando; Timothy L McMurry; Caroline Ochieng; John B Ochieng; Melvin Ochieng; Clayton Onyango; Sandra Panchalingam; Adil Kalam; Fatima Aziz; Shahida Qureshi; Thandavarayan Ramamurthy; James H Roberts; Debasish Saha; Samba O Sow; Suzanne E Stroup; Dipika Sur; Boubou Tamboura; Mami Taniuchi; Sharon M Tennant; Deanna Toema; Yukun Wu; Anita Zaidi; James P Nataro; Karen L Kotloff; Myron M Levine; Eric R Houpt
Journal:  Lancet       Date:  2016-09-24       Impact factor: 79.321
View more
  9 in total

1.  Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya.

Authors:  Elizabeth A Odundo; Hailey P Weerts; Lillian Musila; Lilian Ogonda; Anita M Dreyer; Joerg Schneider; Paula Carranza; Robert W Kaminski
Journal:  mSphere       Date:  2022-05-25       Impact factor: 5.029

2.  Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.

Authors:  Neil Ravenscroft; Martin Braun; Joerg Schneider; Anita M Dreyer; Michael Wetter; Micha A Haeuptle; Stefan Kemmler; Michael Steffen; Dominique Sirena; Stefan Herwig; Paula Carranza; Claire Jones; Andrew J Pollard; Michael Wacker; Michael Kowarik
Journal:  Glycobiology       Date:  2019-08-20       Impact factor: 4.313

3.  A murine model of diarrhea, growth impairment and metabolic disturbances with Shigella flexneri infection and the role of zinc deficiency.

Authors:  Pedro Henrique Q S Medeiros; Solanka E Ledwaba; David T Bolick; Natasa Giallourou; Lauren K Yum; Deiziane V S Costa; Reinaldo B Oriá; Eileen M Barry; Jonathan R Swann; Aldo Ângelo M Lima; Hervé Agaisse; Richard L Guerrant
Journal:  Gut Microbes       Date:  2019-02-03

Review 4.  Challenges of Developing Novel Vaccines With Particular Global Health Importance.

Authors:  Penny M Heaton
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

5.  Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach.

Authors:  Abolfazl Hajialibeigi; Jafar Amani; Seyed Latif Mousavi Gargari
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-16       Impact factor: 4.813

6.  A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country.

Authors:  Christina W Obiero; Augustin G W Ndiaye; Antonella Silvia Sciré; Bonface M Kaunyangi; Elisa Marchetti; Ann M Gone; Lena Dorothee Schütte; Daniele Riccucci; Joachim Auerbach; Allan Saul; Laura B Martin; Philip Bejon; Patricia Njuguna; Audino Podda
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

7.  SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.

Authors:  Bakhos Jneid; Audrey Rouaix; Cécile Féraudet-Tarisse; Stéphanie Simon
Journal:  PLoS Negl Trop Dis       Date:  2020-05-28

8.  Increasing the Affinity of an O-Antigen Polysaccharide Binding Site in Shigella flexneri Bacteriophage Sf6 Tailspike Protein.

Authors:  Sonja Kunstmann; Olof Engström; Marko Wehle; Göran Widmalm; Mark Santer; Stefanie Barbirz
Journal:  Chemistry       Date:  2020-05-19       Impact factor: 5.236

9.  Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.

Authors:  Robert W Frenck; Michelle Dickey; Akamol E Suvarnapunya; Lakshmi Chandrasekaran; Robert W Kaminski; Kristen A Clarkson; Monica McNeal; Amanda Lynen; Susan Parker; Amy Hoeper; Sachin Mani; Alan Fix; Nicole Maier; Malabi M Venkatesan; Chad K Porter
Journal:  mSphere       Date:  2020-09-23       Impact factor: 4.389
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.